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Mouse tissue kallikreins (Klks) are members of a large, multigene family consisting of 37 genes, 
26 of which can code for functional proteins. Mouse tissue kallikrein 5 (Klk5) has long been thought 
to be one of these functional genes, but the gene product, mK5, has not been isolated and char-
acterized. In the present study, we prepared active recombinant mK5 using an Escherichia coli
expression system, followed by column chromatography. We then determined the biochemical and 
enzymatic properties of purified mK5. mK5 had trypsin-like activity for Arg at the P1 position, and 
its activity was inhibited by typical serine protease inhibitors. mK5 degraded gelatin, fibronectin, 
collagen type IV, high-molecular-weight kininogen, and insulin-like growth factor binding protein-
3. Our data suggest that mK5 may be implicated in the process of extracellular matrix remodeling.
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INTRODUCTION
Mouse tissue kallikreins (Klks) are members of a large, 
multigene family located as a gene cluster in cytogenic 
region B2 on mouse chromosome number 7 (Diamandis et 
al., 2004; Olsson et al., 2004). Previous studies suggested 
that individual Klk gene products (mKs) are involved in many 
vital functions, such as kinin production, coagulation and 
fibrinolysis, activation and/or inactivation of peptide hor-
mones, regulation of growth factors, and extracellular matrix 
protein turnover (Margolius, 1998). It is now established that 
the mouse has 37 Klk genes, 26 of which can code for func-
tional proteins (Diamandis et al., 2004; Olsson et al., 2004). 
However, only about half of the 26 genes have been char-
acterized to date by molecular biological and biochemical 
approaches. Mouse tissue kallikrein 5 (Klk5) is one of the 
as-yet-uncharacterized Klk genes. At present, the nucleotide 
sequence is the only information available for this particular 
gene, and studies at the protein level are required to deter-
mine its biological role.
Our previous studies documented the expression of 
Klk21 (Matsui and Takahashi, 2001), Klk24 (Matsui et al., 
2005a, b), and Klk27 (Matsui et al., 2000) in the testis and 
their implications in the function of this male reproductive 
organ. In an attempt to examine by RT-PCR whether or not 
the Klk genes described above are expressed in other 
mouse tissues, we happened to isolate a Klk5 fragment from 
the uterus, suggesting that mK5 may play a role in the 
female reproductive system. To establish a basis for further 
physiological studies of mK5, we prepared active recombi-
nant mK5 for biochemical characterization. The present data 
suggest that mK5 may play a role in various biological pro-
cesses.
MATERIALS AND METHODS
Expression vector construction
The expression vector for mK5 was prepared basically in the 
same way as for mK21 (Matsui and Takahashi, 2001). Briefly, a 
cDNA corresponding to amino acid residues 18–261 of the Klk5
gene, including the pro-enzyme region (DDBJ/EMBL/GenBank 
databases NM 008456), was inserted into the EcoRI and HindIII
sites of pET30a (Novagen, Madison, WI). A sense primer 5’-CCG-
GAATTCGCACCTCCAGTCCAA-3’, which includes the EcoRI site, 
and an antisense primer 5’-CCCAAGCTTTCAGGCATTTTTAGC-
TAT-3’, which includes the HindIII site, were synthesized. PCR 
using KOD plus DNA polymerase (Toyobo, Osaka, Japan) was per-
formed using mouse skeletal muscle cDNA as the template with the 
above primers to create EcoRI sites at the 5’ ends and HindIII sites 
at the 3’ ends. The PCR conditions were as follows: 3 min at 94°C, 
followed by 30 cycles of 30 sec at 94°C, 30 sec at 55°C, and 1 min 
at 68°C. The reaction product was sequentially digested with EcoRI 
and HindIII, then gel purified and ligated in frame between the EcoRI 
and HindIII sites of pET30a. The orientation and sequence of the 
cDNA in the vector plasmid were confirmed by DNA sequencing.
Production and purification of active mK5
The ligated vector (pET30a-mK5) was transformed to E. coli 
strain BL21. The cells were grown at 37°C, induced with isopropyl-
1-thio-β-D-galactoside, harvested by centrifugation, and lysed by 
freeze-thawing. The samples were washed twice with 0.5% Triton 
X-100, solubilized in 50 mM Tris-HCl (pH 7.8) containing 6 M urea 
and 0.5 M NaCl, and incubated for 12 h at room temperature in the 
same buffer containing 6 M urea and 0.5 M NaCl. The solubilized 
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samples were fractionated on a Ni2+-chelate column (5-ml volume) 
(Novagen) previously equilibrated with 50 mM Tris-HCl (pH 7.8) 
containing 0.5 M NaCl and 6 M urea (Matsui and Takahashi, 2001). 
Elution was conducted with 50 mM histidine in the same buffer con-
taining 0.5 M NaCl and 6 M urea. Eluted protein was extensively 
dialyzed against 50 mM Tris-HCl (pH 8.0). The protein thus pre-
pared was a fusion protein containing at the N-terminus 51 extra 
amino acids, all of which originated from the plasmid sequence, in 
addition to the complete pro-mK5 sequence. This fusion protein was 
then incubated in 50 mM Tris-HCl (pH 8.0) with trypsin-Sepharose 
4B, and the resulting active mK5 enzyme preparation was further 
purified by column chromatography on a Resource Q column (1-ml 
bed volume) (AKTA FPLC system) previously equilibrated with 50 
mM Tris-HCl (pH 8.0). The materials retained were eluted with a lin-
ear gradient of 0–0.5 M NaCl in the same buffer. One-milliliter frac-
tions were collected and the enzyme activity of mK5 was assayed 
with a synthetic substrate, Pro-Phe-Arg-MCA, containing 4-methyl-
coumaryl-7-amide (MCA) (Peptide Institute, Osaka, Japan).
Enzyme activity
Recombinant mK5 activity was determined according to the 
method of Barrett (1980) with a slight modification. Briefly, the reac-
tion solution contained 0.1 M Tris-HCl buffer (pH 8.0), 0.1 mM MCA 
substrate, and the enzyme sample in a final volume of 0.5 ml. The 
reaction was initiated by the addition of the substrate and stopped 
by the addition of 2.5 ml of 30 mM sodium acetate buffer (pH 4.3) 
containing 100 mM monochloroacetic acid. The release of fluoro-
phore 7-amino-4-methylcoumarin (AMC) was measured by spec-
trofluorometry at an excitation wavelength of 370 nm and an emis-
sion wavelength of 460 nm.
Kinetic parameters
Kinetic parameters were determined for various MCA sub-
strates. Initial velocities, extrapolated from plots of product versus 
time, were transformed into double-reciprocal plots. Maximum 
velocities (Vmax), Km, and kcat values were obtained from the inter-
cepts of these plots. The active mK5 concentration was determined 
using the active-site titrant p- nitrophenyl-p’-guanidinobenzoate HCl 
according to the method of Chase and Shaw (1967).
Inhibition of mK5 by protease inhibitors
Active mK5 (0.1 μg) was pre-incubated with various concentra-
tions of protease inhibitors at 37°C for 15 min in 0.1 M Tris-HCl 
buffer (pH 8.0). After addition of 0.1 mM Pro-Phe-Arg-MCA, the 
residual enzyme activity was measured.
Degradation of protein substrates by mK5
Gelatin zymography was performed according to the method 
previously described by Heussen and Dowdle (1980). Briefly, mK5 
was electrophoresed on 12% SDS-PAGE gels containing 1 mg/ml 
type A porcine skin gelatin (Sigma, St. Louis, MO) under non-reduc-
ing conditions. After electrophoresis, gels were washed twice in 
2.5% Triton X-100 for 30 min, and then incubated with shaking in 
0.1 M glycine-NaOH (pH 8.3) for 18 h at 37°C. The gels were 
stained with 0.25% Coomassie Brilliant Blue to visualize zones of 
lysis.
Casein (Wako Pure Chemical Industries Ltd., Osaka, Japan) 
was added to mK5 at a ratio of 10:1 (w/w) in 50 mM Tris-HCl buffer 
(pH 8.0), and the mixtures were incubated at 37°C. Aliquots 
removed at different time points were analyzed by SDS-PAGE and 
Coomassie Brilliant Blue staining.
Degradation of fibronectin and laminin was performed as pre-
viously described by Rajapakse et al. (2005). Briefly, 4 μg of human 
plasma fibronectin (Chemicon, Temecula, CA), and 4 μg mouse 
laminin (Biomedical Technologies Inc., Stoughton, MA) were each 
incubated for 18 h at 37°C in 20 μl of 50 mM Tris-HCl buffer (pH 
8.0) with 400 ng of mK5. The reactions were stopped by the addi-
Fig. 1. Purity of purified recombinant mK5. Purified active mK5 
was subjected to SDS-PAGE analysis under reducing (lane 2) and 
non-reducing (lane 3) conditions and visualized by Coomassie Bril-
liant Blue R-250 staining. Lane 1, molecular mass standards (kDa).
Table 1. Kinetic parameters of mK5 as measured on MCA-con-
taining substrates
Substrates Vmax Km kcat kcat/Km
μmol/min/mg mM min–1 mM–1·min–1
Pro-Phe-Arg-MCA 1.5 0.03 39 1300
Z-Phe-Arg-MCA 0.3 0.13 7.6 58
Z-Leu-Arg-MCA 0.1 0.05 2.7 54
Pyr-Gly-Arg-MCA 0.1 0.03 1.6 53
Z-Val-Val-Arg-MCA 0.2 0.11 4.7 43
Boc-Val-Leu-Lys-MCA ND
Boc-Glu-Lys-Lys-MCA ND
Suc-Leu-Leu-Val-Tyr-MCA ND
Ac-Ile-Glu-Thr-Asp-MCA ND
Suc-Ala-Ala-Pro-Phe-MCA ND
Z, benzyloxycarbonyl; Pyr, pyroglutamyl; Boc, tert-butyloxycarbonyl; 
Suc, succinyl; Ac, acetyl; ND, not determined because of no significant 
activity.
Table 2. Effects of protease inhibitors on mK5 activity
Inhibitor Concentration Inhibition (%)
DFP 2.0 mM 87
Leupeptin 0.1 mM 70
Aprotinin 0.1 mg/ml 34
Antipain 0.2 mM 13
SBTI 0.1 mg/ml  0
Benzamidine 1.0 mM  0
E-64 0.5 mM 12
o-Phenanthroline 2.0 mM 10
Pepstatin 0.1 mM  0
TPCK 0.2 mM 14
TLCK 0.2 mM  7
EDTA 0.1 mM  0
Chymostatin 0.2 mM  0
DFP, diisopropyl fluorophosphate; SBTI, soybean trypsin inhibitor; 
TPCK, Nα-p-tosyl-L-phenylalanine chloromethyl ketone; TLCK, 
Nα-p-tosyl-L-phenylalanine chloromethyl ketone; EDTA, ethylene-
diamine tetraacetic acid
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tion of SDS sample buffer, and the reaction mixtures were boiled 
and subjected to SDS-PAGE. After electrophoresis, gels were 
stained with 0.25% Coomassie Brilliant Blue.
The effect of mK5 on collagen types I and IV was examined 
according to the method described previously by Ogiwara et al. 
(2005). Briefly, 25 μg of FITC-conjugated bovine collagen types I 
and IV (Yagai Corporation, Yamagata, Japan) were incubated with 
500 ng of mK5 for 16 h at 33°C in 100 μl of 50 mM Tris-HCl buffer 
(pH 8.0). After incubation, the reactions were terminated by adding 
300 μl of stopping reagent (42% ethanol, 50 mM Tris-HCl (pH 9.5), 
and 0.2 M NaCl). Samples were incubated on ice for 10 min, and 
then centrifuged at 10,000×g for 10 min. Aliquots of the resulting 
supernatants were diluted to a volume of 3.0 ml with distilled water, 
and the fluorescence was measured at an excitation wavelength of 
459 nm and an emission wavelength of 520 nm.
Five micrograms of purified high-molecular-weight kininogen 
(Calbiochem, La Jolla, CA) were incubated at 37°C with 500 ng of 
active mK5 in 0.1 M Tris-HCl buffer, pH 8.0. Aliquots were removed 
Fig. 2. Degradation by mK5 of extracellular matrix and plasma proteins. (A) Gelatin zymography of mK5. Purified mK5 (0.5 μg) was loaded on 
SDS-PAGE gels containing 1 mg/ml gelatin. Electrophoresis was conducted under non-reducing conditions. The arrow indicates the band pro-
duced by gelatinolytic activity of mK5. Positions of protein molecular-mass standards (kDa) are indicated to the left. (B) Effect of mK5 on 
fibronectin. Human fibronectin was separately incubated without (lane 2) or with (lane 3) mK5 for 18 h at 37°C and was subjected to SDS-
PAGE under reducing conditions followed by Coomassie Brilliant Blue R-250 staining. Lane 1, molecular-mass standards (kDa). The arrow and 
asterisk indicate the intact and degraded forms of fibronectin, respectively. (C) Effect of mK5 on collagens. FITC-conjugated collagens type I 
and type IV were incubated without mK5 (-mK5) and with mK5 (+mK5) for 18 h at 33°C, and the fluorescence intensities of the supernatants 
were measured. Values of means±SEM from three separate experiments are shown. (D) Effect of mK5 on high-molecular-weight kininogen. 
The kininogen was incubated with mK5 at 37°C for 0 h (lane 2), 0.5 h (lane 3), 1 h (lane 4), 2 h (lane 5), 4 h (lane 6), or 6 h (lane 7) and was 
subjected to SDS-PAGE under reducing conditions followed by Coomassie Brilliant Blue R-250 staining. Lane 8, incubation for 6 h without 
mK5. Lane 1, molecular-mass standards (kDa). The arrow and asterisks indicate the intact and degraded forms of kininogen, respectively.
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at various time intervals, the reactions were stopped by the addition 
of SDS sample buffer, and the samples were analyzed by SDS-
PAGE followed by Coomassie Brilliant Blue staining.
Twenty-five nanograms of human insulin-like growth factor 
binding protein-3 (IGFBP-3) (Genzyme, Cambridge, MA) were incu-
bated with 10–80 ng of recombinant mK5 at 37°C in 20 μl of 0.1 M 
Tris-HCl (pH 8.0). The reaction was stopped by the addition of SDS 
sample buffer. The reaction mixtures were boiled, separated on 
12% SDS-PAGE, and transferred to a polyvinylidene difluoride 
transfer (PVDF) membrane (Millipore). The blotted membrane was 
incubated with goat anti-human IGFBP-3 (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA) at a 1:1000 dilution and subsequently 
with donkey anti-sheep/goat IgG (Amersham Pharmacia, Biotech, 
Tokyo, Japan). Immunoreactive signals were detected using an 
ECL Western Blot Detection Kit (Amersham Biosciences, Bucking-
hamshire, England) according to the protocol provided by the man-
ufacturer.
The action of mK5 on human single-chain tissue-type plasmi-
nogen activator (American Diagnostica Inc., Greenwich, CT) was 
examined according to the method described previously by Ohnishi
et al. (2004).
RESULTS
Preparation of mK5
In order to obtain a Klk5 cDNA encoding mK5, we con-
ducted RT-PCR using the primer set described in Materials 
and Methods. Total RNAs isolated from salivary glands and 
skeletal muscles of adult mice were used as templates. PCR 
products amplified from the RNAs were found by sequence 
analyses to contain two mouse Klk species, Klk1 and Klk5. 
In the present study, a full-length cDNA isolated from mouse 
skeletal muscle was used for subsequent experiments.
The recombinant protein was expressed in E. coli 
(BL21) transformed with the vector pET30a-mK5, and the 
enzyme was purified as described in Materials and Methods. 
SDS-PAGE analysis of the active enzyme sample eluted 
from a Resource Q column gave a single polypeptide band. 
The apparent molecular mass was estimated to be 28.5 kDa 
under reducing conditions and 25.5 kDa under non-reducing 
conditions (Fig. 1).
Enzymatic properties of mK5
The enzyme showed no detectable activity loss for at 
least 2 months when stored at –20°C. The electrophoretic 
pattern did not change under such storage conditions.
The enzyme activity of the recombinant mK5 was mea-
sured at various pHs using Pro-Phe-Arg-MCA as the sub-
strate. Activity was detected over a pH range of 7–10, with 
the optimum pH at 9.5
Fluorogenic peptide substrates with the AMC cleavage 
group were tested with mK5 to determine its kinetic con-
stants (Table 1). Pro-Phe-Arg-MCA was very rapidly hydro-
lyzed. Other substrates, i.e., Z-Phe-Arg-MCA, Z-Leu-Arg-
MCA, Pyr-Gly-Arg-MCA, and Z-Val-Val-Arg-MCA, were 
hydrolyzed by mK5 to a lesser extent. Among the substrates 
hydrolyzed, the highest kcat value and lowest Km value were 
obtained with Pro-Phe-Arg-MCA. Substrates containing Lys 
at the P1 position were not hydrolyzed. The enzyme showed 
no activity for the synthetic substrates tested that contained 
tetrapeptides.
The enzyme activity of mK5 was strongly inhibited by 
diisopropyl fluorophosphate (DFP) and leupeptin (Table 2). 
A slight inhibition was observed with aprotinin. None of the 
other inhibitors tested showed significant inhibition of mK5 
activity. Assays of two different batches of enzyme prepara-
tion gave the same results.
Our results described above suggest that mK5 is a 
serine protease with strict trypsin-like cleavage specificity.
Hydrolysis of protein substrates by mK5
Zymographic analysis using gelatin was conducted for 
mK5. A single lytic band was seen at a position correspond-
Fig. 3. Action of mK5 on human recombinant IGFBP-3. (A) Human IGFBP-3 (25 ng) was incubated for 2 h at 37°C with the indicated amounts 
of mK5 in 20 μl of 100 mM Tris-HCl (pH 8.0) and was subjected to SDS-PAGE followed by Western blot analysis using anti IGFBP-3 antibody. 
(B) IGFBP-3 (25 ng) was incubated with mK5 (40 ng) at 37°C for the periods indicated at the top of the figure and was subjected to SDS-PAGE/
Western blot analysis as described in (A). In both panels, the positions of molecular-mass protein standards (kDa) are indicated to the left, and 
intact IGFBP-3 and its degraded products (31 and 17 kDa) to the right.
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ing to Mr=25.5 kDa (Fig. 2A). Incubation of intact fibronectin 
(Mr=220 kDa) with mK5 generated two degradation prod-
ucts (Mr=200 and 190 kDa) (Fig. 2B). mK5 cleaved type IV 
but not type I collagen (Fig. 2C). High-molecular-weight kin-
inogen was a substrate for mK5 (Fig. 2D). Casein and lami-
nin were resistant to mK5 (data not shown). mK5 did not 
convert the single-chain tissue-type plasminogen activator 
to the two-chain form of the enzyme (data not shown).
The effect of mK5 on IGFBP-3 was examined. The 
enzyme degraded the intact protein (Mr=41 kDa) in a time-
dependent as well as in a dose-dependent manner, with the 
concomitant production of 31 and 17 kDa fragments (Fig. 3A 
and 3B).
DISCUSSION
The mouse Klk5 gene was previously identified as a 
member of the tissue kallikrein multigene family located on 
chromosome 7 (Mason et al., 1983). Based on the nucle-
otide sequence of Klk5, the gene product mK5 was postu-
lated to be a functional protease. However, little information 
on this protein was currently available. To our knowledge, 
there had been only one study of this protein, which dealt 
with the mRNA expression of the kallikrein in the mouse 
uterus and decidua (Chan et al., 1999). Since our laboratory 
is interested in the roles of proteases, including tissue kal-
likreins, in uterine function, we decided to characterize mK5 
biochemically.
mK5 hydrolyzed the synthetic substrate Pro-Phe-Arg-
MCA with a kcat/Km value (mM–1·min–1) of 1300, which was 
approximately 25 times greater than the values for the other 
substrates tested, indicating that Pro-Phe-Arg-MCA was the 
best substrate. mK21 (Matsui and Takahashi, 2001) and 
mK24 (Matsui et al., 2005a, b), both of which have been 
recently characterized in our laboratory, also showed strong 
activity for this substrate. Like mK21 and mK24, mK5 does 
not cleave Lys-X bonds at all. Table 1 indicates that mK5 is 
highly specific for the hydrolysis of peptide bonds at the car-
boxyl side of arginine residues.
The serine protease nature of mK5 was evident from 
strong inhibition by the protease inhibitors DFP and leupep-
tin. However, some other typical serine protease inhibitors, 
such as SBTI and benzamidine, did not affect mK5 activity. 
The resistance of mK5 to these latter two inhibitors was 
rather surprising, because they substantially inhibited the 
previously characterized mK21 and mK24 (Matsui and 
Takahashi, 2001; Matsui et al., 2005a, b). In this regard, we 
should note our recent observation that mK1 (true mouse 
tissue kallikrein) is also resistant to SBTI and benzamidine 
(our unpublished data). The fact that mK5 resembles mK1 
in its behaviors toward protease inhibitors may indicate that 
mK5 and mK1 have highly similar protein structures. Indeed, 
recent studies by Olsson and Lundwall (2002) on the orga-
nization and evolution of mouse Klk genes have established 
that Klk1 (coding mK1) and Klk5 (coding mK5) are located 
alongside each other, and that they are structurally closest 
among the mouse Klk genes.
The present study clearly demonstrates that mK5 hydro-
lyzes various proteins, including ECM proteins (gelatin, 
fibronectin, and collagen type IV), high-molecular-weight 
kininogen, and IGFBP-3. These facts suggest that mK5 may 
play roles in a variety of biological processes.
Fibronectin is an adhesive cell-surface protein important 
for the interaction of cells with adjacent cells or ECM com-
ponents. Degradation of this protein causes the disintegra-
tion of local ECM environments, leading to increased mobil-
ity of the cells residing in the ECM. Such an event is 
particularly important in the process of ECM remodeling. 
The present finding that mK5 can degrade fibronectin indi-
cates that the protease may be involved in the ECM remod-
eling process. The finding that mK5 shows collagenolytic 
activity for collagen type IV is consistent with this idea.
Another interesting finding is that mK5 cleaves IGFBP-
3. IGFBP-3 is a member of a family of peptides that have a 
strong affinity with IGF-I and IGF-II, and it plays an inhibitory 
role in the activity of IGF. It is generally believed that IGFBP 
proteolysis can reverse the inhibition due to the increased 
concentration of free IGFs near their receptor. The involve-
ment of many proteases in IGFBP proteolysis has been 
reported (Firth and Baxter, 2002). Our data suggest that 
mK5 is another candidate protease for the degradation of 
IGFBP-3. IGFBP-3 hydrolysis by mK5 produced two major 
polypeptides (31 and 17 kDa), pointing to a cleavage at a 
single peptide bond by mK5. We previously reported that 
IGFBP-3 is cleaved by mK21 (Matsui and Takahashi, 2001). 
Interestingly, the hydrolysis patterns of IGFBP-3 appear to 
be the same between mK21 and mK5. The human IGFBP-
3 preparation used in this study contains various sites 
susceptible to proteases. Because mK5 specifically cleaved 
Arg-X bonds and because IGFBP-3 is reported to be hydro-
lyzed by many trypsin-like proteases at Arg97-Ala98, we ten-
tatively suggest this peptide bond may be the site of cleav-
age. However, the validity of this assumption needs to be 
established by future experiments. In short, mK5 could be a 
protease regulating the activity of IGFs through the degra-
dation of IGFBP-3.
In this study, we observed that mK5 hydrolyzes high-
molecular-weight kininogen. However, the biological signifi-
cance of this activity is unknown at present.
In summary, this report describes the first characteriza-
tion of recombinant mK5, which is encoded by an as-yet-
unexamined mouse tissue kallikrein gene (Klk5). Our study 
demonstrates the serine protease nature of mK5 with cleav-
age specificity for Arg-X bonds and suggests that mK5 may 
play a role in the ECM remodeling process. Our data should 
be helpful for future physiological studies of mK5.
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